Tag: Anticoagulants
Management of Antithrombotics in GI Bleed, Endoscopy Addressed
Guideline addresses management of anticoagulants, antiplatelets during acute gastrointestinal bleeding and in the elective endoscopy setting
NOAC Use Not Tied to ICH in Stroke Patients Treated With Alteplase
Recent use of non-vitamin K antagonist oral anticoagulant not linked to increased risk for intracranial hemorrhage with IV alteplase
DOACs Cut Recurrent VTE in Adults With Cancer-Related Thrombosis
Direct oral anticoagulants reduce recurrent VTE events by 41 percent, with no significant increase in major bleeding, compared to dalteparin
NOACs May Be Better Choice for Patients With A-Fib and DM
Risks for diabetes complications, mortality lower with non-vitamin K antagonist oral anticoagulants versus warfarin
Bleeding Events Up With Full-Dose Thromboprophylaxis in COVID-19
Almost all hospitalized COVID-19 patients with a bleeding event were receiving mechanical ventilation, full-dose anticoagulation
Adding a P2Y12 Inhibitor Does Not Improve Outcomes in COVID-19
Adding a P2Y12 inhibitor to a therapeutic dose of heparin does not improve outcomes among non-critically ill patients hospitalized for COVID-19
Frail Patients With Nonvalvular A-Fib Less Likely to Receive Anticoagulants
Frail patients with nonvalvular atrial fibrillation also less likely to receive a direct oral anticoagulant versus warfarin
Recurrent VTE Rate Higher Than Expected for Subsegmental PE
Prospective cohort study restricted to patients with low-risk subsegmental pulmonary embolism managed without anticoagulation
AHA: Oral Milvexian Promising for Prevention of VTE
In patients undergoing knee arthroplasty, postoperative incidence of venous thromboembolism lower with milvexian versus enoxaparin
Therapeutic Heparin May Benefit Moderately Ill COVID-19 Inpatients
Among those with increased D-dimer levels, no reduction seen in primary composite outcome at 28 days, but odds of death decreased
